Journal of Breast Cancer最新文献

{"title":"Decision-Making Patterns for Clinically Node-Positive, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: Insights From a Survey of Breast Cancer Experts.","authors":"Yoonwon Kook, Minji Lee, Seung Ho Baek, Henry Gomez, Soong June Bae, Joon Jeong, Sung Gwe Ahn","doi":"10.4048/jbc.2025.0091","DOIUrl":"https://doi.org/10.4048/jbc.2025.0091","url":null,"abstract":"<p><strong>Purpose: </strong>In hormone receptor (HR)-positive, human epidermal growth factor receptor 2-negative (HER2-) breast cancer, the omission of chemotherapy has become a viable option for select patients. However, when lymph node (LN) metastasis is suspected at diagnosis, the optimal initial treatment strategy (upfront surgery, neoadjuvant chemotherapy, or genomic testing) remains controversial. This study aimed to assess the preferences of multinational breast cancer specialists and to identify the factors influencing clinical decisions in this setting.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted among breast cancer specialists at two time points: November 2023 (via the Korean Breast Cancer Society) and April 2024 (following the Asian Breast Cancer Network meeting at Global Breast Cancer Conference 2024). The questionnaire presented 18 case scenarios that reflected varying patient ages, tumor sizes, nodal involvement, and pathological features. Respondents selected their preferred initial treatment strategy. Consensus was defined as ≥ 60% agreement. Univariate and multivariate logistic regression analyses were performed to identify the demographic factors associated with responses in the non-consensus scenarios.</p><p><strong>Results: </strong>A total of 189 responses were analyzed. Consensus was consistently observed in postmenopausal patients and in cases involving small low-grade tumors with limited nodal suspicion. However, the responses varied between peri- and pre-menopausal patients, particularly in the intermediate-risk scenarios. Multivariate analysis revealed that clinician specialty, nationality, affiliation, and experience significantly influenced treatment choice. Notably, clinicians from other Asian countries and medical oncologists showed a greater preference for upfront surgery than for neoadjuvant chemotherapy in younger patients with aggressive tumor features.</p><p><strong>Conclusion: </strong>The findings reveal both consensus and variability in clinical decision-making for HR+HER2- breast cancer with suspected LN involvement among multinational breast cancer specialists. This underscores the need for enhanced international collaboration and clear guidance in intermediate-risk settings. The incorporation of diagnostic tools such as multigene assays may further support individualized treatment decisions.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Clinical Application of Artificial Intelligence in Breast Imaging: Current Insights, Challenges, and Future Directions.","authors":"Yu-Mee Sohn, Eun Jee Song","doi":"10.4048/jbc.2025.0123","DOIUrl":"https://doi.org/10.4048/jbc.2025.0123","url":null,"abstract":"<p><p>Artificial intelligence (AI) is used in various areas of radiology, particularly in breast imaging, starting with mammography and extending to ultrasonography (US) and magnetic resonance imaging (MRI). This overview aims to examine the introduction, applications, and challenges of AI in breast imaging. This narrative outlines the applications of AI in various modalities-including mammography, US, and MRI-and discusses its indications, ongoing challenges, and future perspectives. AI has been used for identification, classification, detection, diagnosis, breast density assessment, treatment response, and prediction of prognosis. AI can help radiologists avoid missed diagnoses due to heavy workloads and enhance workflow efficiency. The integration of AI software into daily practice, along with further validation and refinement, is necessary to support radiologists' workflows.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Neutrophil-Lymphocyte Ratio Change After Short-Term Chemotherapy in <i>De Novo</i> Stage IV Breast Cancer Patients.","authors":"Haena Shin, Sei-Hyun Ahn, Sae Byul Lee, Il-Yong Chung, Hee Jeong Kim, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Jae Ho Jeong, Jin Hee Ahn, Kyung Hae Jung, Sung-Bae Kim, Jisun Kim","doi":"10.4048/jbc.2024.0267","DOIUrl":"https://doi.org/10.4048/jbc.2024.0267","url":null,"abstract":"<p><p>We aimed to investigate whether the neutrophil-to-lymphocyte ratio (NLR) change after the first cycle of palliative chemotherapy can be a prognostic indicator in <i>de novo</i> stage IV breast cancer. We retrospectively reviewed 218 patients treated between January 1997 and December 2012 at Asan Medical Center, Seoul, Korea. The NLR change (ΔNLR = NLR after first cycle of chemo - initial NLR [iNLR]) was significantly inversely associated with breast cancer specific survival (BCSS) (<i>p</i> = 0.031). The 1-, 3-, and 5-year BCSS rates of patients in the increased NLR group were 78.4%, 37.8%, and 25.7%, and 88.9%, 55.6%, and 35.4%, respectively, in the other group (<i>p</i> = 0.035, 0.014, and 0.043, respectively). Multivariate analysis suggested that NLR was an independent prognostic factor (hazard ratio [HR], 1.748; 95% confidence interval [CI], 1.084-2.818). When patients were divided into four groups combining iNLR and ΔNLR, patients in high iNLR & increased NLR group (HR, 4.294; 95% CI, 1.586-11.629) had worst prognosis compared to patients in low iNLR & stationary or decreased NLR groups.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Predicting Additional Residual Nodal Disease With a Metastatic Sentinel Node Biopsy or Targeted Axillary Dissection After Neoadjuvant Chemotherapy.","authors":"Neslihan Cabıoğlu, Hasan Karanlık, Abdullah Iğci, Mahmut Müslümanoğlu, Okan Mustafa Gürsoy, Mustafa Tükenmez, Nusret Can Polat, Enver Özkurt, Selman Emiroğlu, Nilüfer Yıldırım, Ahmet Serkan Ilgün, Semen Önder, Ravza Yılmaz, Memduh Dursun, Duygu Has Simşek, Pınar Saip, Adnan Aydıner, Aysel Bayram, Baran Mollavelioğlu, Kamuran Ibiş, Seden Küçücük, Vahit Özmen","doi":"10.4048/jbc.2025.0052","DOIUrl":"https://doi.org/10.4048/jbc.2025.0052","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate whether specific clinicopathological characteristics are associated with a lower likelihood of additional positive nodes (APNs) on completion axillary lymph node dissection (cALND).</p><p><strong>Methods: </strong>A total of 497 patients with cT1-4/N1-3 disease underwent cALND following a positive sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NAC). The APN rate was assessed based on findings from the cALND.</p><p><strong>Results: </strong>The median age was 47 (21-84). The overall APN rate was 67.6%. Patients with cT1-2 disease, a breast pathological complete response, removal of > two nodes via SLNB or TAD, only one metastatic node identified at SLNB or TAD, a lymph node ratio (LNR) < 50%, or low-volume metastatic disease (including isolated tumor cells [ITCs] or micro-metastases) at SLNB or TAD were significantly less likely to have APN on cALND (<i>p</i> < 0.05). Multivariate logistic regression analysis showed a decreased likelihood of APN on cALND in patients with cT1-2 disease (odds ratio [OR], 0.56; 95% confidence interval [CI], 0.35-0.89; <i>p</i> = 0.016), ITCs or micro-metastases (OR, 0.32; 95% CI, 0.12-0.84; <i>p</i> = 0.021), and an LNR < 50% at SLNB or TAD (OR, 0.22; 95% CI, 0.14-0.37; <i>p</i> < 0.001). Among subgroups, patients with cT1-2/N1 disease and either LNR < 50% or ITC/micro-metastasis, as well as patients with cT1-3 cN1 disease undergoing TAD with LNR < 50%, had APN rates on cALND of 23.4%, 26.7%, and 16.7%, respectively.</p><p><strong>Conclusion: </strong>In patients with a positive SLNB or TAD after NAC, an APN rate < 30% on cALND can be achieved in certain subgroups with favorable features, including cT1-2 and cN1 disease and low-volume metastatic burden.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy Boost to Clinically Positive Internal Mammary Lymph Nodes: An Effective Non-Surgical Alternative?","authors":"Caglayan Selenge Beduk Esen, Yasin Ozyurek, Sezin Yuce Sari, Melis Gultekin, Gokhan Ozyigit, Ferah Yildiz","doi":"10.4048/jbc.2024.0304","DOIUrl":"10.4048/jbc.2024.0304","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the effect of radiation therapy (RT) boost sequences and doses to internal mammary (IM) lymph nodes (LNs) on oncologic outcomes and toxicity in patients with clinically IMLN-positive breast cancer.</p><p><strong>Methods: </strong>Twenty-six patients with positive IMLNs at diagnosis who were treated between 2013 and 2022 were retrospectively evaluated. After systemic therapy and surgery, RT was applied to the whole breast or chest wall, including the axillary, supraclavicular, and IM lymphatics. An RT boost to the IMLNs was administered either sequentially or as a simultaneous integrated boost (SIB). Treatment outcomes, prognostic factors, and toxicity profiles were analyzed.</p><p><strong>Results: </strong>A complete response (CR) and partial response (PR) in metastatic IMLNs were observed in 17 patients (65.4%) and 5 patients (19.2%) following systemic therapy, respectively. One patient (3.8%) had stable disease, while two patients (7.7%) experienced disease progression in the IMLNs.After a median follow-up of 67 months, regional recurrence, distant metastasis, or both occurred in 1 (3.8%), 1 (3.8%), and 2 (7.7%) patients, respectively. The 5-year overall survival (OS) and disease-free survival (DFS) rates were 86.7% and 76.4%, respectively. The absence of extracapsular extension in axillary LNs was associated with improved OS and DFS. A CR or PR to systemic treatment in IMLNs was associated with improved DFS only. The boost sequence had no significant effect on survival, organ-at-risk doses, or cardiac toxicity.</p><p><strong>Conclusion: </strong>An RT boost to IMLNs without surgical resection provides excellent oncologic outcomes with acceptable toxicity. While the SIB technique reduces the number of treatment fractions, it did not result in superior oncologic outcomes compared to the sequential boost. Further prospective studies are needed to investigate the role of RT boost sequencing to the IMLNs.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"228-241"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144753487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD39 and CD73 Expression in Breast Cancer: CD73 as a Favorable Prognostic Factor in HER2-Positive Tumors.","authors":"Eunhye Kang, Suk-Won Suh, Yoo Shin Choi, Hee Sung Kim, Min Kyoon Kim","doi":"10.4048/jbc.2025.0040","DOIUrl":"10.4048/jbc.2025.0040","url":null,"abstract":"<p><strong>Purpose: </strong>CD39 (<i>ENTPD1</i>, ectonucleoside triphosphate diphosphohydrolase-1) and CD73 (<i>NT5E,</i> 5'-nucleotidase) are mediators of adenosine release in the tumor microenvironment (TME), and adenosine has the effect of overcoming anti-tumor immunity. This CD39-CD73-adenosine pathway is thought that play a role in immune suppression and promotion of tumor growth and infiltration. This study investigated the clinical and prognostic significance of CD39 and CD73 in breast cancer.</p><p><strong>Methods: </strong>This study included 472 patients with primary invasive breast cancer who received surgical treatment at the Breast Cancer Clinic at Chung-Ang University Hospital from June 2010 to May 2017. Using a tissue microarray, biomarker immunostaining was performed for CD39 and CD73. We assessed the expression ratio of CD39 and CD73 in breast cancer subgroups, and investigated the association between disease-free survival (DFS) and the expression of CD39 and CD73.</p><p><strong>Results: </strong>The expression ratio of CD39 and CD73 in breast cancer subgroups differed according to hormone receptor status and human epidermal growth factor receptor 2 (HER2) status. In the case of CD39, the high-level rate was increased in estrogen receptor (ER)/progesterone receptor (PR) positive (<i>p</i> = 0.001, <i>p</i> = 0.009), and HER2 negative (<i>p</i> < 0.001) breast cancer. In contrast, in the case of CD73 expressed in tumor-infiltrating lymphocyte (TIL), the expression rate was increased in ER/PR negative (<i>p</i> < 0.001), and HER2 positive (<i>p</i> < 0.001), breast cancer. High CD39 expression was significantly associated with lower stage (<i>p</i> < 0.001), but there was no relationship CD39 expression and survival. In patients with HER2-positive breast cancer, CD73 expression in TIL was associated with lower stage (<i>p</i> = 0.024), and better survival in DFS analysis (<i>p</i> = 0.015).</p><p><strong>Conclusion: </strong>In conclusion, the expression ratio of CD39 and CD73 in breast cancer subgroups differed according to hormone receptor status and HER2 status, and CD73 expression in TILs associated with a trend toward favorable prognosis in HER2 positive breast cancer.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"28 4","pages":"255-267"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research on the Emotional Stress of Pregnancy-Associated Breast Cancer Patients and Its Effects on Child developmenT: The RESPECT.","authors":"Ah Yoon Kim, Ju Yeon Kim, Jae Ho Jeong, Soojin Ahn, Seonok Kim, Yungil Shin, Hee Jeong Kim, Hyo-Won Kim","doi":"10.4048/jbc.2025.0050","DOIUrl":"10.4048/jbc.2025.0050","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer (BC) is the most common cancer occurring during pregnancy. With delayed childbirth, pregnancy-associated breast cancer (PABC) incidence is expected to increase. It can be challenging for mothers undergoing cancer treatment and coping with disease progression to focus on parenting. The child may be affected by the mother's ongoing treatment both prenatally and postnatally. This study aims to investigate the biopsychosocial development of children born to patients with PABC, the emotional stress of patients.</p><p><strong>Methods: </strong>This ambispective cohort study combines a retrospective analysis of previously collected data from January 2019 to December 2029 with the prospective recruitment and follow-up of new patients. Patients diagnosed with PABC within the past 5 years will be recruited from hospitals and patient associations. Recruitment and follow-up will occur from July 1, 2024, to December 31, 2029, with 80 participants targeted for both the subject and control groups.</p><p><strong>Discussion: </strong>This study aims to provide long-term insights into the biopsychological development of children born to PABC patients, as well as the emotional states and QoL. The findings are expected to optimize biopsychosocial development, enhance family well-being, and guide breast cancer patients in making informed pregnancy decisions.</p><p><strong>Trial registration: </strong>Clinical Research information Service Identifier: KCT0010225.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"28 4","pages":"280-287"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Pectoral Nerve and Paravertebral Blocks for Postoperative Pain Management in Breast Surgery: A Multicentre Randomised Double-Blind Trial.","authors":"Roberto Dossi, Edoardo Tasciotti, Kuijk van Sander, Paolo Maino, Vladimir Reyes Lozano, Andrea Saporito, Eva Koetsier","doi":"10.4048/jbc.2025.0060","DOIUrl":"10.4048/jbc.2025.0060","url":null,"abstract":"<p><strong>Purpose: </strong>Pectoral nerve (PECS) blocks have gained popularity for pain management in breast cancer surgery because of their ease of use and lower risk profile. However, their efficacy compared with that of paravertebral block (PVB) remains uncertain. This study aimed to evaluate the non-inferiority of the PECS block to PVB for postoperative analgesia.</p><p><strong>Methods: </strong>This prospective, randomized, double-blind trial included adult patients (American Society of Anesthesiologists status 1-3) scheduled for elective breast cancer surgery. The patients were randomized to receive either a PECS block or PVB. The primary outcome was block success, defined as a Visual Analogue Scale pain score of < 30 at 30 minutes, 6 hours, and 24 hours postoperatively. The secondary outcomes included opioid consumption, block performance time, functional recovery, and patient satisfaction.</p><p><strong>Results: </strong>Of the 42 patients, 23 received a PECS block and 19 received PVB. Successful blocks were achieved in 69.6%, 81.8%, and 77.3% of patients with PECS blocks and 63.2%, 68.4%, and 88.9% of patients with PVB at 30 minutes, 6 hours, and 24 hours, respectively. The non-inferiority of PECS was significant at 30 minutes and 6 hours but inconclusive at 24 hours. The PECS blocks were performed faster (7 vs. 14 minutes, <i>p</i> < 0.001). Opioid consumption, global satisfaction, and functional recovery were comparable with no reported complications.</p><p><strong>Conclusion: </strong>Our study shows that the PECS block is non-inferior to the PVB in managing postoperative pain after breast surgery, offering advantages such as reduced administration time and a favorable safety profile. These findings support the integration of the PECS block into pain management strategies for breast cancer surgery.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT02645474.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"28 4","pages":"268-279"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Desmoid-Type Fibromatosis Masquerading as Disease Progression in Metastatic Breast Cancer in a Patient on Ribociclib Therapy: A Case Report.","authors":"Ha Rim Ahn, Ae Ri Ahn, Hyun Jo Youn","doi":"10.4048/jbc.2025.0107","DOIUrl":"10.4048/jbc.2025.0107","url":null,"abstract":"<p><p>Ribociclib combined with an aromatase inhibitor (AI) is widely used as first-line therapy for hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER-2)-negative metastatic breast cancer. Desmoid-type fibromatosis (DTF) is a rare, locally invasive soft-tissue tumor that accounts for only 0.2% of all breast neoplasms and can mimic malignancy upon imaging. A 44-year-old premenopausal woman with HR-positive, HER2-negative bone-only metastatic breast cancer developed a rapidly growing breast mass after 30 cycles of ribociclib with an AI. Imaging suggested cancer progression, necessitating total mastectomy. However, postoperative pathology confirmed DTF, which is a rare occurrence that has not been previously reported. Appropriate therapeutic planning and follow-up for metastatic breast cancer should include histopathological diagnosis, when necessary, beyond clinical and imaging assessments.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"28 4","pages":"288-294"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary Team Intervention: Catalysts for Changing Prognosis in Advanced Breast Cancer.","authors":"Jun-Sheng Zheng, Hui Fu, Zhao Bi, Zhi-Qiang Shi, Jin-Ming Yu, Peng-Fei Qiu, Yong-Sheng Wang","doi":"10.4048/jbc.2025.0001","DOIUrl":"10.4048/jbc.2025.0001","url":null,"abstract":"<p><strong>Purpose: </strong>Multidisciplinary team (MDT) discussions are standard in cancer care; however, their effect on advanced breast cancer (ABC) prognosis is not well-documented. This study examined the impact of MDT intervention on ABC patient survival.</p><p><strong>Methods: </strong>A retrospective analysis of ABC patients diagnosed 2018 to 2021 was conducted by dividing them into MDT and non-MDT groups. Kaplan-Meier analysis was used to compare progression-free survival (PFS) and overall survival (OS) between the groups. Prognostic factors were evaluated using multivariate Cox regression analysis with subgroup analysis and 1:1 propensity score matching (PSM) to control for confounders.</p><p><strong>Results: </strong>Total 707 patients were included, with 72.8% (515/707) underwent MDT intervention. After a median follow-up of 43.73 months (interquartile range, 34.87-55.67 months), MDT intervention improved the median PFS (12.00 vs. 8.00 months; hazard ratio [HR], 0.75 [95% confidence interval {CI}, 0.63-0.89]; <i>p</i> = 0.001) and median OS (55.67 vs. 40.07 months; HR, 0.77 [95% CI, 0.61-0.97]; <i>p</i> = 0.030). Multivariate Cox analysis showed MDT as an independent factor for disease progression control (HR, 0.82 [95% CI, 0.68-0.98]; <i>p</i> = 0.041), but not for OS (HR, 0.88 [95% CI, 0.69-1.12]; <i>p</i> = 0.286). Subgroup analysis indicated that MDT benefited patients aged ≤ 39 years, those with disease status (<i>de novo</i> metastatic breast cancer), post-menopausal status, T4 stage, N3 stage, G3, visceral metastasis, > one organ metastasis and first-line systemic treatment, regardless of PFS or OS. After PSM, 172 matched patients were in the cohort. MDT still significantly controlled disease progression (12.00 vs. 8.00; HR, 0.74 [95% CI, 0.59-0.93]; <i>p</i> = 0.009) but did not significantly impact the OS (49.00 vs. 39.00; HR, 0.80 [95% CI, 0.59-1.08]; <i>p</i> = 0.121).</p><p><strong>Conclusion: </strong>MDT effectively controlled the disease progression and improved OS in specific patient subgroups.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"242-254"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}